Vitruvias Therapeutics Completes $11.5M Series A Financing

Vitruvias Therapeutics, Inc., an Auburn, Ala.-based generic pharmaceutical company with a focus on sterile injectables, completed a $11.5m Series A financing.

The round was led by JW Asset Management LLC, and Perceptive Advisors. In conjunction with the funding, Jason Wild of JW Asset Management, Michael Altman of Perceptive Advisors and Ed Schutter, CEO of Arbor Pharmaceuticals, Inc., will join Vitruvias Therapeutics’ Board of Directors.

The company intends to use the funds to complete multiple projects already under development.

Led by Carl Whatley, President, Bryce Harvey and Roger Graben, PhD., Vitruvias is a generic pharmaceutical company which utilizes domestic and international partnerships to develop, manufacture, and market technically difficult generic products. Founded in 2013, the company’s primarily focus is on products in the generic sterile injectable market. Vitruvias received its first approval in September 2017, and anticipates additional approvals in 2018.



Join the discussion